

# CITATION REPORT

List of articles citing

**Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators**

**DOI: 10.1016/s0002-8703(96)90365-8  
American Heart Journal, 1996, 131, 350-5.**

**Source:** <https://exaly.com/paper-pdf/26749796/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
133	Antihypertensive drugs. <b>1997</b> , 20, 194-199		
132	Heart Failure in Women. <b>1997</b> , 9, 511-519		18
131	Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. <b>1997</b> , 30, 612-5		24
130	Chagas' heart disease and the autonomic nervous system. <b>1998</b> , 66, 123-7		43
129	Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. <b>1998</b> , 11, 1080-6		42
128	The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. <b>1998</b> , 11, 1433-41		16
127	ACE inhibitor-induced angioedema: more common than previously thought. <b>1998</b> , 12, 10-12		
126	ACE inhibitor-induced angioedema. Incidence, prevention and management. <b>1998</b> , 18, 171-88		159
125	Failure of women's hearts. <b>1999</b> , 99, 2334-41		119
124	Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. <b>1999</b> , 20, 1182-90		84
123	Angioedema due to ACE inhibitors: increased risk in patients of African origin. <b>1999</b> , 48, 861-5		103
122	Neue Aspekte der Hyperkaliämie. <b>1999</b> , 36, 361-366		
121	Concern for azotemia with angiotensin-converting enzyme inhibitors: public health implications and clinical relevance. <i>American Heart Journal</i> , <b>1999</b> , 138, 801-3	4.9	12
120	Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). <i>American Heart Journal</i> , <b>1999</b> , 138, 849-55	4.9	126
119	Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. <b>2000</b> , 36, 1105-11		30
118	Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. <b>2000</b> , 109, 489-92		23
117	The stress of being a doctor: steroid excretion rates in internal medicine residents on and off duty. <b>2000</b> , 109, 492-4		17

116 Antihypertensive drugs. **2000**, 23, 217-224

115 [Evidence based medical treatment of heart failure]. **2001**, 54, 715-34

6

114 Clinical profile and management of heart failure: rural community hospital vs. metropolitan heart center. *European Journal of Heart Failure*, **2001**, 3, 611-7

12.3 29

113 Gender and drug treatment as determinants of mortality in a cohort of heart failure patients. **2001**, 17, 329-35

3

112 Failing ageing hearts. **2001**, 22, 1978-90

24

111 Are women different than men? Aspects of heart failure in special populations: elderly women. **2002**, 1, 29-31

2

110 Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus. **2002**, 42, 754-61

16

109 A benefit-risk assessment of agents used in the secondary prevention of stroke. **2002**, 25, 943-63

3

108 Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. **2003**, 9, 224-9

25

107 Angioedema asociado a losartán. **2003**, 94, 566-568

106 Utilidad del perindopril en insuficiencia cardíaca leve-moderada en la práctica clínica diaria. Estudio MÉRICA. **2003**, 203, 3-9

105 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies. **2003**, 15, 423-37, vii-viii

104 Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction : meta-analysis of randomised clinical trials. **2003**, 26, 895-908

19

103 Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. **2003**, 362, 772-6

1362

102 Gender differences in patients with heart failure. **2003**, 2, 7-18

108

101 Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. *European Journal of Heart Failure*, **2003**, 5, 261-70

12.3 98

100 Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. **2003**, 285, R255-61

69

99 Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. **2004**, 22, 820-8

215

98	Handbook of Drug Interactions. <b>2004</b> ,		11
97	An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. <b>2004</b> , 10, 499-509		141
96	Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. <b>2004</b> , 19, 684-91		33
95	Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure. <b>2004</b> , 10, 259-64		20
94	References. <b>2004</b> , 43, 268-290		
93	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. <b>2004</b> , 24, 168-75		56
92	Heart failure in women. <b>2004</b> , 88, 1321-45, xii		63
91	If It Is Not Cough, It Must Be Dysgeusia: Differing Adverse Effects of Angiotensin-Converting Enzyme Inhibitors in the Same Individual. <b>2004</b> , 5, 107-110		18
90	Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. <b>2004</b> , 96, 321-33		21
89	Improving outcomes in heart failure in the community: long-term survival benefit of a disease-management program. <b>2005</b> , 127, 2042-8		21
88	Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <b>2005</b> , 112, 3391-9		93
87	Acute adverse reactions associated with angiotensin-converting enzyme inhibitors: genetic factors and therapeutic implications. <b>2005</b> , 6, 1851-6		17
86	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation; endorsed by the Heart Rhythm Society. <b>2005</b> , 112, e154-235		1915
85	Ramipril induced polyserositis with pericardial tamponade and pleural effusion. <b>2005</b> , 102, 355-6		3
84	Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 12-20	3-3	205
83	ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, e1-82	15.1	1119
82	Hyperkalemia: a review. <b>2005</b> , 20, 272-90		110
81	Angiotensin-converting enzyme inhibitors. <b>2006</b> , 226-237		

80	Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. <i>American Heart Journal</i> , <b>2006</b> , 152, 705-12	4.9	55
79	Incidence and Characteristics of Angioedema Associated With Enalapril. <b>2006</b> , 2006, 80-81		
78	Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. <b>2006</b> , 13, 325-31		17
77	Difficulties in maintaining potassium homeostasis in patients with heart failure. <b>2006</b> , 29, 388-92		12
76	Drug safety in cardiovascular disease: a call to ACTION. <b>2006</b> , 20, 9-10		0
75	Antihypertensive medication prescribing in 27,822 elderly Canadians with diabetes over the past decade. <b>2006</b> , 29, 836-41		23
74	Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 1120-7	12.3	59
73	Pharmacologic prevention of aspiration pneumonia: a systematic review. <b>2007</b> , 5, 352-62		31
72	Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. <b>2007</b> , 16, 55-64		61
71	Does heart failure therapy differ according to patient sex?. <b>2007</b> , 30, 301-5		2
70	Inhibition of the renin-angiotensin system and chronic kidney disease. <b>2008</b> , 40, 1015-25		19
69	Aliskiren: the first renin inhibitor for clinical treatment. <b>2008</b> , 7, 399-410		167
68	Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. <b>2008</b> , 8, 35-44		42
67	Management of patients with heart failure in clinical practice: differences between men and women. <b>2008</b> , 94, e10		65
66	Sex differences in response to chronic heart failure therapies. <b>2008</b> , 6, 555-65		15
65	2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. <b>2009</b> , 119, e391-479		1178
64	Enalapril-induced cough is associated with non-severe heart failure. <b>2009</b> , 135, 275-6		7
63	2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, e1-e90	15.1	1224

62	Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure. <b>2009</b> , 10, 206-19		13
61	Quantitative structure activity relationship analysis of angiotensin II AT1 receptor antagonists. <b>2010</b> , 19, 475-489		10
60	Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. <b>2010</b> , 33, 62-6		19
59	Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. <b>2010</b> , 123, 1016-30		77
58	CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 929-36	12.3	57
57	ACE-inhibitor therapy at relatively high doses and risk of renal worsening in chronic heart failure. <b>2011</b> , 97, 507-16		2
56	The effect of sex/gender on cardiovascular pharmacology. <b>2011</b> , 17, 1095-107		26
55	Future of personalized pharmacotherapy in chronic heart failure patients. <b>2011</b> , 7, 357-79		4
54	Therapeutic potential of c-Myc inhibition in the treatment of hypertrophic cardiomyopathy. <b>2011</b> , 2, 133-44		10
53	Influence of sex on treatment and outcome in chronic heart failure. <b>2012</b> , 30, 182-92		11
52	Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <b>2012</b> , 30, e156-66		92
51	Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1401-9	12.3	21
50	Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. <b>2012</b> , 110, 383-91		113
49	A Picture is Worth a Thousand Tables. <b>2012</b> ,		9
48	Chronic urticaria and use of statins. <b>2012</b> , 2, 227-9		1
47	Kidney ADP-Ribosyl Cyclase Inhibitors as a Therapeutic Tool for Diabetic Nephropathy. <b>2012</b> ,		
46	Protective effects of enalapril, an angiotensin-converting enzyme inhibitor, on multiple organ damage following scald injury in rats. <b>2012</b> , 59, 307-13		2
45	Quantitative structure-activity relationship of 2-alkyl-4-(biphenylmethoxy) pyridine derivatives with AT1 receptor antagonistic activity. <b>2012</b> , 19, 1212-1218		5

44	Improvement in antioxidant activity, angiotensin-converting enzyme inhibitory activity and in vitro cellular properties of fermented pepino milk by Lactobacillus strains containing the glutamate decarboxylase gene. <b>2013</b> , 93, 859-66		11
43	Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. <b>2013</b> , 28, 442-52		6
42	Comparative QSAR and pharmacophore analysis for a series of 2,4-dihydro-3H-1,2,4-triazol-3-ones derivatives as angiotensin II AT1 receptor antagonists. <b>2014</b> , 23, 2486-2502		8
41	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <b>2015</b> , 36, 2576-84		129
40	Angiotensin-converting enzyme inhibitors. <b>2016</b> , 472-497		
39	Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit. <b>2017</b> , 38, 155-161		22
38	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). <b>2018</b> , 11, e004745		34
37	Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction. <b>2018</b> , 38, 29-41		5
36	Question 1: How safe are ACE inhibitors for heart failure in children?. <b>2018</b> , 103, 106-109		4
35	QSAR study of 2,4-dihydro-3H-1,2,4-triazol-3-ones derivatives as angiotensin II AT1 receptor antagonists based on the Monte Carlo method. <b>2018</b> , 29, 441-449		34
34	Long-Term Administration of Angiotensin (1-7) to Mice Reduces Oxidative Stress Damage in the Kidneys and Prevents Renal Dysfunction. <b>2018</b> , 2018, 1841046		7
33	PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS. <i>Rational Pharmacotherapy in Cardiology</i> , <b>2018</b> , 14, 167-175	0.5	1
32	Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 745-754	3.7	24
31	Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update. <i>Pharmaceutics</i> , <b>2018</b> , 10,	6.4	23
30	Serum Electrolyte Levels and Ventricular Arrhythmia. <i>Angiology</i> , <b>2019</b> , 70, 87-88	2.1	1
29	Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 258-266	7.9	27
28	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 29-40	15.1	86
27	Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. <i>Revista Portuguesa De Cardiologia</i> , <b>2020</b> , 39, 517-541	1	3

26	Design and synthesis of two new steroid derivatives with biological activity on heart failure via the M-muscarinic receptor activation. <i>Steroids</i> , <b>2020</b> , 158, 108620	2.8	4
25	Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 942-952	3.7	1
24	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1357-1365	12.3	18
23	The Importance of Complement Testing in Acquired Angioedema Related to Angiotensin-Converting Enzyme Inhibitors. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 947-955	5.4	6
22	Design and Synthesis of an Aniline Derivative with Biological Activity on Heart Failure. <i>Combinatorial Chemistry and High Throughput Screening</i> , <b>2021</b> , 24, 220-232	1.3	
21	Isolation, Purification and Characterization of Proteins in Beßrita[Banana (Musa acuminata (AAA) Beßrita]Pulp with Bioactive Peptides Exhibiting Antihypertensive and Antioxidant Activities. <i>Applied Sciences (Switzerland)</i> , <b>2021</b> , 11, 2190	2.6	1
20	Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 560-571	3.8	15
19	Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system. <i>European Journal of Pharmacology</i> , <b>2021</b> , 897, 173961	5.3	0
18	Cardiovascular Drugs. <b>2012</b> , 285-381		1
17	Kardiologie. <b>2008</b> , 343-387		2
16	Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril. French General Hospitals National College of Cardiologists. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 33, 953-9	3.1	10
15	Sushchestvuyut li perspektivy primeneniya petlevykh diuretikov dlya lecheniya arterial'noy gipertenzii?. <i>Cardiosomatics</i> , <b>2011</b> , 2, 76-80	0.4	1
14	Cardiovascular Drugs. <b>2004</b> , 219-292		
13	Kardiologie. <b>2004</b> , 313-356		
12	Angiotensin receptor blockers for chronic heart failure. <b>2006</b> , 127-171		
11	Physiopathologie des effets secondaires aigus des inhibiteurs de l'enzyme de conversion de l'angiotensine.. <i>Bulletin De L'Academie Nationale De Medecine</i> , <b>2007</b> , 191, 1433-1444	0.1	
10	Drugs Used to Treat Hypertension, Heart Failure, and Angina Pectoris. <b>2009</b> , 1-196		
9	Medical Therapy for Heart Failure. <b>2010</b> , 29-68		



8 Gendersverschillen bij Hartfalen. **2011**, 63-72

7 Using Exploratory Visualization in the Analysis of Medical Product Safety in Observational Healthcare Data. **2012**, 391-413

6 Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. *Revista Portuguesa De Cardiologia (English Edition)*, **2020**, 39, 517-541 0

5 Sex Differences in Heart Failure. *Journal of Cardiac Failure*, **2021**, 3:3 3

4 Impacto de la presión arterial en el tratamiento y pronóstico de los pacientes tratados con sacubitrilo/valsartán. *REC: CardioClinics*, **2022**, 0.2 0

3 The Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women-Chapter 6: Sex- And Gender-Specific Diagnosis and Treatment. *CJC Open*, **2022**, 2 0

2 Changes in Cardiac Function During the Development of Uremic Cardiomyopathy and the Effect of Salvianolic Acid B Administration in a Rat Model. *Frontiers in Veterinary Science*, 9, 3.1 2

1 Biological Activity of a 4-Hydroxy-Furanyl-Benzamide Derivative on Heart Failure. 0